The purpose of this Alzheimer’s Disease-Related Dementia (ADRD) initiative is to promote the development and distribution of innovative technologies, methods, protocols, and biomedical materials that enhance combined human neuropathology and neuroimaging research aimed at understanding the vascular pathogensis and pathophysiology of anti-Aβ monoclonal antibody (mAb) induced Amyloid Related Imaging Abnormalities (ARIA).
Resources developed under this NOFO are intended to expand the broader research community’s capacity to perform research aimed at neuropathologically-informed understanding of the vascular pathogenesis and pathophysiology of clinically relevant, in vivo neuroimaging findings.
This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.
Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
Application Due Date: May 31, 2024
Application budgets are limited to $1.0M in direct costs per year and need to reflect the actual needs of the proposed project.
The scope of the proposed project should determine the project period. The maximum project period is five years.